Share price information

Amryt Pharma is traded on Nasdaq and the London Stock Exchange’s AIM Market

ADS Conversion Frequently Asked Questions

Download ADS Conversion Frequently Asked Questions document >>

Major shareholders

Major shareholders are as follows (interest as at 4 January 2021).

Name Number of shares % of issued share capital
Funds managed by Athyrium
Capital Management, LP
44,286,346 24.8%
Funds managed by Highbridge Capital Management LLC 15,732,313 8.8%
Novelion Therapeutics Inc 12,490,250 7.0%
Edgepoint Investment Group Inc. 12,126,650 6.8%
Stonepine Capital Management, LLC 11,082,415 6.2%
Software AG-Stiftung 10,212,153 5.7%
Funds managed by UBS O’Connor LLC 9,950,000 5.6%
Amati 6,860,513 3.8%
AXA Investment Management 6,494,164 3.6%

On August 31 2021 the issued share capital comprised 316,496,087 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company at August 31, 2021 was 316,496,087.

This figure of 316,496,087 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

Pursuant to the AIM rules, and insofar as the Company is aware, as at 30 June 2021, 28.39% of the Company’s issued share capital is not in public hands.

Restrictions: there are no restrictions on the transfer of Ordinary Shares.
Takeover Code: the Company is subject to the City Code on Takeovers and Mergers.